UC WAR. CALL 12/24 IDP/ DE000HD31TF8 /
2024-09-02 5:41:01 PM | Chg.-0.0400 | Bid6:05:04 PM | Ask6:05:04 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
0.9100EUR | -4.21% | 0.9000 Bid Size: 12,000 |
0.9400 Ask Size: 12,000 |
BIOGEN INC. DL -,000... | 220.00 - | 2024-12-18 | Call |
GlobeNewswire
07-30
New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI® (lecane...
GlobeNewswire
07-30
Biogen, Beckman Coulter and Fujirebio to Collaborate on Blood-Based Biomarkers and Test for Tau Path...
GlobeNewswire
07-26
Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union
GlobeNewswire
06-28
“LEQEMBI®” (Lecanemab) for the Treatment of Alzheimer’s Disease Launched in China
GlobeNewswire
06-24
TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA®, Approved in the European Union
GlobeNewswire
06-10
FDA Accepts Eisai’s Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application f...
GlobeNewswire
06-03
Biogen and Delta Flight Products to Collaborate with Advocates and Patients to Inform the Future of ...
GlobeNewswire
05-30
Biogen Receives European Commission Approval for QALSODY® (tofersen), the First Therapy to Treat a R...
GlobeNewswire
05-22
Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Im...
GlobeNewswire
05-16
Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lat...
GlobeNewswire
05-15
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Su...
GlobeNewswire
04-25
Biogen Receives Positive CHMP Opinion for TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEM...
GlobeNewswire
04-23
Recludix Pharma Announces the Appointment of Dr. Ajay Nirula, Accomplished Pharma Executive and Immu...
GlobeNewswire
03-06
New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) i...
GlobeNewswire
03-04
Biogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (...
GlobeNewswire
02-23
Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positiv...